A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus Infection
Status:
Active, not recruiting
Trial end date:
2023-01-19
Target enrollment:
Participant gender:
Summary
This Phase 2a study will assess the safety, antiviral activity, and pharmacokinetics (PK) of
ABI-H2158 administered once daily for up to 72 weeks in combination with entecavir (ETV) in
participants with chronic hepatitis B virus (HBV) infection.